GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Broncus Holding Corp (HKSE:02216) » Definitions » Net Income Including Noncontrolling Interests

Broncus Holding (HKSE:02216) Net Income Including Noncontrolling Interests : HK$-119.25 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Broncus Holding Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Broncus Holding's Net Income Including Noncontrolling Interests for the six months ended in Dec. 2024 was HK$-57.21 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-119.25 Mil.

Broncus Holding Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Broncus Holding's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Broncus Holding Net Income Including Noncontrolling Interests Chart

Broncus Holding Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial -378.18 -1,841.95 -218.27 -219.39 -118.96

Broncus Holding Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -93.24 -115.39 -104.34 -62.04 -57.21

Broncus Holding Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-119.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Broncus Holding Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Broncus Holding's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Broncus Holding Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Broncus Holding Corp (HKSE:02216) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
HKSE:02500 HKSE:02407 HKSE:06922 HKSE:02170 HKSE:06609 HKSE:06118 HKSE:01612 HKSE:02393 HKSE:02297 HKSE:01696 ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
No. 88 Jiangling Road, Xixing Street, Room 801, 8th Floor, Building 8, Binjiang District, Hangzhou, CHN
Website
https://www.broncus.com
Broncus Holding Corp is focused on provision of interventional treatment of Chronic Obstructive Pulmonary Disease and lung cancer. It engages in the field of Interventional Pulmonology, providing solutions for lung diseases in China and globally. Its products portfolio includes the InterVapor Thermal Vapor Treatment System the only implantable medical device to treat COPD; BroncAblate Radiofrequency Ablation System the transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation Radiofrequency Ablation System the self-developed targeted radiofrequency ablation system in China to reduce the risk of acute exacerbation of COPD.
Executives
Computershare Hong Kong Trustees Limited 2301 Trustee
Zi Zhenjun
Xu Hong 2101 Beneficial owner
Xin Nuo Tong Investment Limited 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd. 2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p. 2101 Beneficial owner
Qiming Gp Iv, L.p. 2201 Interest of corporation controlled by you
Dinova Capital Limited
Dinova Venture Partners Gp Iii, L.p.
Broncus Biomedical Limited
Dinova Healthcare Gamma Fund (usd) L.p.
Qm12 Limited 2101 Beneficial owner
Dinova Healthcare (hong Kong) Co., Limited
Lake Bleu Capital (hong Kong) Limited 2102 Investment manager
Hang Zhou De Nuo Shang Wu Zi Xun Zi Xun You Xian Gong Si

Broncus Holding Headlines

No Headlines